Clinical Trials Browser

Phase 3 × Interventional × Plasma cell × Clear all

NCT03301220 2026-03-18

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

390 enrolled 12 charts 1 FDA

Smoldering Multiple Myeloma

NCT05083169 2026-03-18

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 1 FDA

Multiple Myeloma

NCT06980480 2026-03-18

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04512235 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT05257083 2026-03-17

CARTITUDE-6

Phase 3 Active not recruiting

Multiple Myeloma

NCT05552976 2026-03-17

SUCCESSOR-2

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT04181827 2026-03-16

CARTITUDE-4

Phase 3 Active not recruiting

419 enrolled 10 charts

Multiple Myeloma

NCT05438043 2026-03-16

A Study of Daratumumab

Phase 3 Recruiting

Multiple Myeloma

NCT07393282 2026-03-16

LINKER-SMM2

Phase 3 Not yet recruiting

Smoldering Multiple Myeloma, Multiple Myeloma

NCT03901963 2026-03-13

AURIGA

Phase 3 Active not recruiting

200 enrolled 12 charts

Multiple Myeloma

NCT04923893 2026-03-13

CARTITUDE-5

Phase 3 Active not recruiting

Multiple Myeloma

NCT05827016 2026-03-13

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

Phase 3 Recruiting

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

Phase 3 Recruiting

Multiple Myeloma

NCT05552222 2026-03-12

MajesTEC-7

Phase 3 Recruiting

Multiple Myeloma

NCT05519085 2026-03-11

SUCCESSOR-1

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT03844048 2026-03-06

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06045806 2026-03-05

KarMMa-9

Phase 3 Active not recruiting

Multiple Myeloma

NCT03729804 2026-03-04

(COBRA)

Phase 3 Active not recruiting

Multiple Myeloma

NCT05623020 2026-03-04

MagnetisMM-6

Phase 3 Recruiting

Multiple Myeloma

NCT00602641 2026-03-03

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Active not recruiting

306 enrolled 12 charts

Multiple Myeloma

NCT03937635 2026-03-02

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Phase 3 Recruiting

Smoldering Multiple Myeloma

NCT04566328 2026-03-02

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Phase 3 Recruiting

Multiple Myeloma

NCT06963216 2026-02-27

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Phase 3 Recruiting

Immunoglobulin Light-chain Amyloidosis, Blood Coagulation Disorders, Factor X Deficiency, Hematologic Diseases, Hemorrhagic Disorders

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT03480360 2026-02-19

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Phase 3 Active not recruiting

21 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Lymphoma, Lymphoma, Non-Hodgkin, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell, Primary Myelofibrosis

NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Completed

LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT05243797 2026-02-17

MajesTEC-4

Phase 3 Recruiting

Multiple Myeloma

NCT07258511 2026-02-13

TRIlogy-4

Phase 3 Recruiting

Multiple Myeloma

NCT04162210 2026-02-11

DREAMM-3

Phase 3 Active not recruiting

325 enrolled 10 charts

Multiple Myeloma

NCT03710603 2026-02-10

Perseus

Phase 3 Active not recruiting

709 enrolled 17 charts 1 FDA

Multiple Myeloma

NCT03275285 2026-02-09

IKEMA

Phase 3 Completed

302 enrolled 38 charts 1 FDA

Multiple Myeloma

NCT00572169 2026-02-05

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Phase 3 Active not recruiting

Multiple Myeloma

NCT03617731 2026-02-03

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Phase 3 Active not recruiting

Multiple Myeloma

NCT06152575 2026-02-03

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05020236 2026-02-02

MAGNETISMM-5

Phase 3 Recruiting

Multiple Myeloma

NCT06216158 2026-02-02

Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma

NCT07297329 2026-01-29

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 3 Recruiting

Multiple Myeloma

NCT06932562 2026-01-23

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Phase 3 Recruiting

Multiple Myeloma

NCT01208662 2026-01-22

DFCI 10-106

Phase 3 Active not recruiting

729 enrolled 29 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03652064 2026-01-20

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase 3 Active not recruiting

395 enrolled 1 FDA

Multiple Myeloma

NCT05455320 2026-01-16

MonumenTAL-3

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT03246529 2026-01-15

GENESIS

Phase 3 Active not recruiting

180 enrolled 22 charts

Multiple Myeloma

NCT06679101 2026-01-08

DREAMM-10

Phase 3 Recruiting

Multiple Myeloma

NCT01208766 2026-01-06

HO95

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05675319 2026-01-05

AlloRelapseMM

Phase 3 Terminated

Multiple Myeloma

NCT05317416 2025-12-22

MagnetisMM-7

Phase 3 Active not recruiting

Hematologic Diseases, Multiple Myeloma

NCT03180736 2025-12-19

EMN14

Phase 3 Completed

304 enrolled 19 charts 1 FDA

Multiple Myeloma